Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology - Seite 2
The Novartis Prize for Clinical Immunology 2016 is awarded to Zelig Eshhar (Weizmann Institute of Science, Israel), Carl June (University of Pennsylvania, USA) and Steven Rosenberg (National Institutes of Health, USA) for their work on the pre-clinical and clinical development as well as technological application of cellular immune therapy using Chimeric Antigen Receptor-T cells (CAR-T-cells) for diseases such as cancer.
"Immune disorders destroy the lives of many and increased research in this field is vital," said Hidde Ploegh, Jury chair, "these prestigious awards recognize the outstanding contributions made by the world's top scientists. It is so important that we recognize and reward these exceptional scientists who have paved the way for future research and treatment."
For more information on the prizes go to: http://www.novartisimmunologyprizes.com/
Disclaimer
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "to receive," "will," "upcoming," "opened the door,"
"commitment," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks
and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update it in the future.
Lesen Sie auch
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best
meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies
employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.